Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATOS NASDAQ:ETON NASDAQ:FSDC NASDAQ:INFI NASDAQ:TLSA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATOSAtossa Genetics$0.85-3.5%$0.81$0.55▼$1.66$109.63M1.1482,507 shs749,315 shsETONEton Pharmaceuticals$18.34-0.7%$16.33$5.35▼$21.48$491.84M1.1201,780 shs406,346 shsFSDCFS Development$60.79-2.9%$13.90$9.80▼$13.75$760.85MN/A332,704 shs878,158 shsINFIInfinity Pharmaceuticals$0.07$0.01▼$0.01$726K1.632.58 million shs2.48 million shsTLSATiziana Life Sciences$1.82+2.2%$1.88$0.63▼$2.60$212.66M-0.36330,856 shs278,304 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATOSAtossa Genetics0.00%+1.06%+14.07%+7.43%-40.23%ETONEton Pharmaceuticals0.00%+3.91%+7.31%+35.15%+210.32%FSDCFS Development-2.94%+1.62%+3.53%+17.79%+28.38%INFIInfinity Pharmaceuticals0.00%0.00%0.00%0.00%0.00%TLSATiziana Life Sciences0.00%+7.69%-5.70%+16.67%+70.09%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATOSAtossa Genetics$0.85-3.5%$0.81$0.55▼$1.66$109.63M1.1482,507 shs749,315 shsETONEton Pharmaceuticals$18.34-0.7%$16.33$5.35▼$21.48$491.84M1.1201,780 shs406,346 shsFSDCFS Development$60.79-2.9%$13.90$9.80▼$13.75$760.85MN/A332,704 shs878,158 shsINFIInfinity Pharmaceuticals$0.07$0.01▼$0.01$726K1.632.58 million shs2.48 million shsTLSATiziana Life Sciences$1.82+2.2%$1.88$0.63▼$2.60$212.66M-0.36330,856 shs278,304 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATOSAtossa Genetics0.00%+1.06%+14.07%+7.43%-40.23%ETONEton Pharmaceuticals0.00%+3.91%+7.31%+35.15%+210.32%FSDCFS Development-2.94%+1.62%+3.53%+17.79%+28.38%INFIInfinity Pharmaceuticals0.00%0.00%0.00%0.00%0.00%TLSATiziana Life Sciences0.00%+7.69%-5.70%+16.67%+70.09%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATOSAtossa Genetics 3.33Buy$6.17626.60% UpsideETONEton Pharmaceuticals 3.00Buy$29.6761.76% UpsideFSDCFS Development 0.00N/AN/AN/AINFIInfinity Pharmaceuticals 0.00N/AN/AN/ATLSATiziana Life Sciences 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATOSAtossa GeneticsN/AN/AN/AN/A$0.57 per shareN/AETONEton Pharmaceuticals$39.01M12.61N/AN/A$0.94 per share19.51FSDCFS DevelopmentN/AN/AN/AN/AN/AN/AINFIInfinity Pharmaceuticals$2.59M0.00N/AN/A($0.21) per share0.00TLSATiziana Life SciencesN/AN/AN/AN/A$0.04 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATOSAtossa Genetics-$25.50M-$0.23N/AN/AN/AN/A-40.28%-37.10%11/11/2025 (Estimated)ETONEton Pharmaceuticals-$3.82M-$0.16N/A36.68N/A-7.10%-0.73%-0.22%11/11/2025 (Estimated)FSDCFS DevelopmentN/AN/A0.00∞N/AN/AN/AN/AN/AINFIInfinity Pharmaceuticals-$44.37M-$0.46N/AN/AN/A-1,593.93%N/A-113.02%N/ATLSATiziana Life Sciences-$11.86MN/A0.00∞N/AN/AN/AN/A10/13/2025 (Estimated)Latest TLSA, ATOS, ETON, INFI, and FSDC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025ATOSAtossa Genetics-$0.06-$0.07-$0.01-$0.07N/AN/A8/7/2025Q2 2025ETONEton Pharmaceuticals-$0.01-$0.10-$0.09-$0.10$16.71 million$18.93 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATOSAtossa GeneticsN/AN/AN/AN/AN/AETONEton PharmaceuticalsN/AN/AN/AN/AN/AFSDCFS DevelopmentN/AN/AN/AN/AN/AINFIInfinity PharmaceuticalsN/AN/AN/AN/AN/ATLSATiziana Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATOSAtossa GeneticsN/A9.179.17ETONEton Pharmaceuticals1.141.771.16FSDCFS DevelopmentN/A2.912.91INFIInfinity PharmaceuticalsN/A1.651.65TLSATiziana Life SciencesN/A1.021.02Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATOSAtossa Genetics12.74%ETONEton Pharmaceuticals27.86%FSDCFS Development89.82%INFIInfinity Pharmaceuticals22.14%TLSATiziana Life SciencesN/AInsider OwnershipCompanyInsider OwnershipATOSAtossa Genetics7.60%ETONEton Pharmaceuticals16.03%FSDCFS DevelopmentN/AINFIInfinity Pharmaceuticals9.81%TLSATiziana Life Sciences39.82%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATOSAtossa Genetics8129.17 million119.35 millionOptionableETONEton Pharmaceuticals2026.82 million22.52 millionOptionableFSDCFS DevelopmentN/A12.52 millionN/ANot OptionableINFIInfinity Pharmaceuticals3090.76 million81.86 millionOptionableTLSATiziana Life Sciences8116.85 million70.32 millionOptionableTLSA, ATOS, ETON, INFI, and FSDC HeadlinesRecent News About These CompaniesTiziana Life Sciences Ltd (NASDAQ:TLSA) Short Interest Up 20.5% in AugustSeptember 20 at 2:35 AM | americanbankingnews.comTiziana Life Sciences Ltd (NASDAQ:TLSA) Sees Large Increase in Short InterestSeptember 19 at 4:57 PM | marketbeat.comTiziana Life Sciences announces U.S. DoD awarded research grant to study SCISeptember 15, 2025 | msn.comTiziana Life Sciences Secures DoD Grant for Spinal Cord Injury ResearchSeptember 15, 2025 | msn.comTiziana Life Sciences awarded DoD grant to advance intranasal therapy for spinal cord injurySeptember 15, 2025 | proactiveinvestors.comDepartment of Defense Awards Grant to Advance Tiziana Life Sciences Intranasal Anti-CD3 Therapy for Spinal Cord InjurySeptember 15, 2025 | globenewswire.comTiziana Life Sciences reports CEO purchased 14,848 sharesSeptember 10, 2025 | msn.comTiziana Life Sciences Announces Purchase of Shares by Chief Executive OfficerSeptember 9, 2025 | globenewswire.comTiziana Life Sciences Announces Purchase of Shares by Chief Executive OfficerSeptember 9, 2025 | globenewswire.comTiziana Life Sciences Announces Purchase of Shares by ChairmanSeptember 5, 2025 | globenewswire.comTiziana Life Sciences Ltd's (NASDAQ:TLSA) largest shareholders are retail investors with 53% ownership, insiders own 43%September 1, 2025 | finance.yahoo.comTiziana Life Sciences (NASDAQ:TLSA) Trading Down 7.4% - Time to Sell?August 21, 2025 | marketbeat.comTiziana Life Sciences doses first MSA patient in new trial – ICYMIAugust 15, 2025 | proactiveinvestors.comTiziana Life Sciences Initiates Phase 2a Trial for MSA with Intranasal ForalumabAugust 14, 2025 | msn.comTiziana Life doses first patient in Phase 2a trial of intranasal foralumabAugust 14, 2025 | msn.comTiziana Life Sciences doses first patient in Phase 2a MSA trialAugust 14, 2025 | proactiveinvestors.comTiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System AtrophyAugust 14, 2025 | globenewswire.comTiziana Life Sciences Phase 2a multiple system atrophy study green-lit by FDAAugust 11, 2025 | proactiveinvestors.comFDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System AtrophyAugust 11, 2025 | globenewswire.comTiziana Life Sciences reports encouraging results from nasal Alzheimer's treatmentJuly 21, 2025 | proactiveinvestors.comTiziana Life Sciences Announces Immunologic Analysis of Nasal Foralumab in Moderate Alzheimer's PatientJuly 21, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTLSA, ATOS, ETON, INFI, and FSDC Company DescriptionsAtossa Genetics NASDAQ:ATOS$0.85 -0.03 (-3.55%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$0.85 +0.00 (+0.39%) As of 09/19/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.Eton Pharmaceuticals NASDAQ:ETON$18.34 -0.12 (-0.65%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$18.68 +0.34 (+1.85%) As of 09/19/2025 05:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.FS Development NASDAQ:FSDCFS Development Corp. focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the biotechnology sector. The company was founded in 2020 and is based in San Francisco, California.Infinity Pharmaceuticals NASDAQ:INFIInfinity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel medicines for people with cancer. The company's product candidate, including eganelisib (IPI-549), an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. Infinity Pharmaceuticals, Inc. has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Cambridge, Massachusetts.Tiziana Life Sciences NASDAQ:TLSA$1.82 +0.04 (+2.25%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$1.82 +0.00 (+0.27%) As of 09/19/2025 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas FedEx Delivers Good News: The Bottom Is in for This Stock Tesla: 2 Reasons to Love Musk's $1B Buy, 1 Reason to Be Bearish Berkshire-Backed Lennar Slides After Weak Q3 Earnings Azure Leads While AI Excitement Fuels Microsoft Stock Caterpillar Stock Hits All-Time High—Is There More Room to Run? The Fed Cut Rates: What Now for the S&P 500 and Equity Markets? Darden Restaurants: A Textbook Buy-the-Dip Opportunity McDonald’s: New All-Time Highs Are Inevitable Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
